FDA panel recommends Exubera

An FDA Advisory panel recommended that the FDA approve inhaled insulin drug Exubera. If the FDA follows the advisory panel –which it usually, but not always does– it will be a sign that they have not become totally risk averse. As a commenter pointed out in response to yesterday’s post,

Diabetes is a condition with so much morbidity and mortality that the existence of minor problems and the possibility of unforeseen problems are risks people are willing to take.

It’s a good thing if the FDA lets patients take those risks. It’s up to doctors, pharmacists, and the patients themselves to make sure they understand the risks and benefits.

September 9, 2005

Leave a Reply

Your email address will not be published. Required fields are marked *